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Abstract 
Malignancy is a common complication after renal transplantation. However, limited data are 
available on post-transplant malignancy in living kidney transplantation. Therefore, we made a 
plan to evaluate the incidence and types of malignancies, association with the main risk factors 
and patient survival in a large population of living kidney transplantation. We conducted a large 
retrospective multicenter study on 12525 renal recipients, accounting for up to 59% of all 
kidney transplantation in Iran during 22 years follow up period. All information was collected 
from observation of individual notes or computerized records for transplant patients. Two 
hundred and sixty-six biopsy-proven malignancies were collected from 16 Transplant Centers 
in Iran; 26 different type of malignancy categorized in 5 groups were detected. The mean age 
of patients was 46.2±12.9 years, mean age at tumor diagnosis was 50.8±13.2 years and average 
time between transplantation and detection of malignancy was 50.0±48.4 months. Overall 
tumor incidence in recipients was 2%. Kaposis’ sarcoma was the most common type of tumor. 
The overall mean survival time was 117.1 months (95% CI: 104.9-129.3). In multivariate 
analysis, the only independent risk factor associated with mortality was type of malignancy. 
This study revealed the lowest malignancy incidence in living unrelated kidney transplantation. 
Key words: malignancy, kidney transplantation, incidence. 
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INTRODUCTION 
Kidney transplantation is generally accepted as 
the best treatment for patients with end stage renal 
disease (ESRD) requiring renal replacement therapy 
which improves both the quality of life and life span 
of  patients  (1-5).  Although  the  new  and  potent  im-
munosuppressive  agents  have  successfully  reduced 
the  risk  of  rejection  after  kidney  transplantation; 
however, cardiovascular disease, infectious and neo-
plastic complications are increasing (3, 6). Cancer is 
the second cause of death in renal transplant recipi-
ents (2) and it is expected that the mortality due to 
cancer  will  be  moved  to  become  the  first  cause  of 
death  within  the  next  two  decades  (7).  The  overall 
reported post-transplant malignancy incidence varies 
from 2% to 31%; however, it happen in a percentage 
as high as 34-50% among renal transplant recipients 
(RTRs)  followed  for  more  than  20  years  (7).  Many 
studies have demonstrated an increased risk of cancer 
among RTRs when compared with an age- and gen-
der-matched  general  population  or  in  patients  un-
dergoing dialysis (1-4). In general, the risk of devel-
oping  malignancy  in  organ  transplants  is  3-4  times 
greater than general population and the risk of certain 
types of cancer is as high as 20-500 folds (3, 8, 9). 
The majority of the literature on malignancy in 
kidney  transplantation  is  drawn  from  deceased 
transplants  and  limited  data  are  available  on 
post-transplant  malignancy  in  living  kidney  trans-
plantation,  especially  living  unrelated  renal  trans-
plantation (LURT). Although Kasiske et al (2004) (10) 
reported the largest study (n = 35765) about the inci-
dence rates of malignancies among first-time kidney 
recipients, however, living donor transplantation only 
accounted 24% all of them (i.e., n=8584). Furthermore, 
the  other  huge  studies  (11-16)  only  focused  on  de-
ceased kidney transplantation.  
Therefore, we made a plan to evaluate the prev-
alence, incidence, characteristics, potential predictors 
of death, relationship to immunosuppressive drugs, 
common  cancers,  current  opinions  on  management, 
patient survival and the association with the main risk 
factors  of  prognosis  of  malignancy  following  renal 
transplantation, particularly in a large population of 
LURT (10960 cases out of all 12525 RTRs) (17, 18). 
PATIENTS AND METHODS 
Recipient population 
We conducted a large retrospective multicenter 
study on 12525 RTRs, accounting for up to 59% of all 
kidney transplantation in Iran (19), to determine the 
incidence and types of malignancies occurring after 
renal transplantation and their impact on patient and 
graft survival between Oct 1984 and Dec 2008. The 
majority of our patients received a kidney from a liv-
ing  unrelated  donor  (87.5%),  following  9.8%  living 
related and 2.7% deceased donor transplantation. The 
mean age of RTRs was 37.7±15.2 years (range: 3 to 86 
years), 7885 (63%) male and 4640 (37%) female. The 
duration  of  study  was  24  years  and  patients  were 
followed-up until graft loss, patient death or the date 
of  last  visit  subsequently  266  biopsy-proven  malig-
nancies were collected from 16 Transplant Centers in 
Iran. The patient characteristics are shown in Table 1. 
This  study  was  approved  by  the  local  Ethics  Com-
mittee of Baqiyatallah University of Medical Sciences.  
Patients with other organ transplants, history of 
previous  malignancy  and  transplantation  from  de-
ceased donors with past history of malignancy were 
excluded.  
Definition 
1- The definition of acute rejection was based on 
the conventional pathologic criteria, Banff classifica-
tion, and clinical criteria of the reporting centers.  
2-  Treatment  modalities  were  considered  ac-
cording to the type of cancer, staging of disease, and 
involved  organs.  Management  included  a  combina-
tion of reduction, withdrawal or changing of the im-
munosuppressive agents, chemotherapy, radiothera-
py, hormone therapy and surgical resection. 
3-  Non  Kaposi’s  sarcoma  tumors  (non-KS)  in-
cluded SCC (squamouse cell carcinoma), BCC (basal 
cell carcinoma) and melanoma. 
4- Tumors of breast, ovary and uterine in female, 
prostate and seminoma in male and renal cell carci-
noma (RCC) and transitional cell carcinoma (TCC) of 
bladder in both gender were considered as genitou-
rinary  and  reproductive  system  (GU  &  RS)  neo-
plasms. 
5- The term of solid tumors was used for all the 
malignancies  except  for  skin  tumors,  PTLD  (post 
transplantation  lymphoproliferative  disorder)  and 
GU & RS cancers. 
6- Patients with tumor were categorized into 5 
groups according to their type of neoplasm: Non-KS, 
KS, PTLD, GU & RS tumors and solid tumors. 
7- Monoclonal antibody (ATG/ALG) can be re-
quired  for  induction  therapy  and  for  acute  ster-
oid-resistant rejection episodes during the first three 
months  following  kidney  transplantation.  Induction 
therapy with ATG/ALG was used for highly sensi-
tized patients, those receiving kidneys from deceased 
donors  with  delayed  graft  function,  patients  with 
poorly matching living donors, and patients with the 
second or more transplants. None of the patients took 
OKT3.  Journal of Cancer 2012, 3 
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Table 1: Main demographic and clinical characteristics of 266 post-transplant malignancies in living kidney transplant re-
cipients. 
Variables  Number (%)  Cancer  
  KS  Non-KS  PTLD  GU & RS  Solid  p 
Total  84 (31.6)  57 (21.1)  72 (27.1)  25 (9.3)  28 (10.4)   
Gender  Male  180 (67.7)  54 (30)  48 (26.7)  43 (23.9)  14 (7.8)  21 (11.7)  0.01 
Female  86 (32.3)  30 (35.3)  9 (9.4)  29 (34.1)  11 (12.9)  7 (8.2) 
Age  ≤30    33 (12.9)  8 (24.2)  3 (9.1)  18 (54.5)  2 (6.1)  2 (6.1)  0.007 
31-50  117 (45.9)  35 (29.9)  17 (14.5)  36 (30.8)  13 (11.1)  16 (13.7) 
>50  105 (41.2)  36 (34.3)  36 (34.3)  15 (14.3)  8 (7.6)  10 (9.5) 
Graft status  Active  232 (89.6)  73 (31.5)  53 (22.8)  64 (27.6)  20 (8.6)  22 (9.5)  0.02 
loss  27 (10.4)  10 (37)  1 (37)  7 (25.9)  4 (14.8)  5 (18.5) 
Patient status  Died  67 (25.4)  12 (17.9)  1 (1.5)  28 (41.8)  9 (13.4)  17 (25.4)  0.0001 
Alive  197 (74.6)  72 (36.5)  56 (28.4)  43 (21.8)  15 (7.6)  11 (5.6) 
ALG/ATG  No  183 (83.6)  55 (30.1)  46 (25.1)  49 (26.8)  16 (8.7)  17 (9.3)  0.06 
Yes  36 (16.4)  12 (33.3)  2 (5.6)  13 (36.1)  5 (13.9)  4 (11.1) 
Treatment modality  Discontinue   80 (38.6)  23 (28.8)  11 (13.8)  29 (36.3)  6 (7.5)  11 (13.8)  0.002 
  Decrease   74 (27.8)  36 (48.6)  17 (23)  9 (12.2)  5 (6.8)  7 (9.5) 
Change   28 (10.5)  8 (28.6)  6 (21.4)  11 (39.3)  1 (3.6)  2 (7.1) 
unmodified  25 (12.1)  1 (4)  9 (36)  8 (32)  4 (16)  3 (12) 
Response to treat  No  56 (21.1)  6 (10.7)  2 (3.6)  27 (48.2)  6 (10.7)  15 (26.8)  0.0001 f 
Yes  119 (44.7)  49 (41.2)  34 (28.6)  26 (21.8)  7 (5.9)  3 (2.5) 
Relapse  No  18 (85.7)  4 (22.2)  3 (16.7)  7 (38.9)  2 (11.1)  2 (11.1)  0.3 f 
Yes  3 (14.3)  1 (33.3)  2 (66.7)  0  0  0 
Metastasis  No  156 (75.7)  72 (46.2)  53 (34)  19(12.2)  6(3.8)  6 (3.8)  0.0001 f 
Yes  50 (24.3)  11 (22)  3 (6)  14(28)  6(12)  16 (32) 
CMV infection after 
cancer 
No  43 (78.2)  15 (34.9)  5 (11.6)  13(30.2)  7(16.3)  3 (7)  0.8 f 
Yes  12 (21.8)  6 (50)  2 (16.7)  3(25)  1(8.3)  0 
Rejection  No  148 (79.1)  50 (33.9)  35 (23.6)  40(27)  8(5.4)  15 (10.1)  0.06 f 
Yes  39 (20.9)  12 (30.8)  4 (10.3)  12(30.8)  7(17.9)  4 (10.3) 
Immunossuppresive MMF  96 (38.7)  41 (42.7)  16 (16.7)  21(21.9)  7(7.3)  11 (11.5)  0.01 
AZA  152 (61.3)  34 (22.4)  39 (25.7)  47(30.9)  15 (9.9)  17 (11.2) 
f: Fisher, CMV: cytomegalovirus, MMF: mycophenolatemofetil, AZA: azathioprine, ALG/ATG: antilymphocyte/antithymocyte globulin, 
Non-KS: Non Kaposi’s sarcoma, KS: Kaposi’s sarcoma, PTLD: post transplantation lymphoproliferative disorder, GU & RS: genitourinary 
and reproductive system. 
 
Immunosuppression protocols 
The immunosuppressive therapy was based on 
cyclosporine/sirolimus,  mycophenolate  mofetil 
(MMF)/azathioprine (AZA) and steroids. Before 2000, 
patients received dual maintenance immunosuppres-
sion with prednisone and cyclosporine/AZA or triple 
therapy  with  cyclosporine,  prednisone,  and  AZA. 
Afterwards, the majority  of patients received cyclo-
sporine, prednisone, and MMF as well (20). 
STATISTICS 
Data  were  analyzed  with  SPSS  version  17.0. 
Quantitative  variables  were  expressed  as  mean  ± 
standard  deviation,  whereas  qualitative  variables 
were shown as number and percentage. Continuous 
data were compared by Student’s t-test, and catego-
rized  data  were  analyzed  using  the  Chi-square  or 
Fisher’s exact test. 
Cancer-free patient survival rate was defined as 
the time from diagnosis of the tumor to death. The 
Kaplan-Meier method was used to calculate actuarial 
survival curves, and univariate comparison between 
groups was carried out by using the log-rank test. Cox 
proportional hazards survival regression model was 
used to evaluate the effect of risk factors on patient 
survivals. The significance level was set at P <0.05. 
RESULTS 
Patient population 
The patients with malignancy were followed af- Journal of Cancer 2012, 3 
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ter diagnosis of cancer for a median follow up time of 
22 months (min 1 month and max 168 months). The 
male/female ratio was 2.1:1. The mean age of patients 
was 46.2±12.9 years (range 12-72 years); on average, 
men  were  older  than  women  (47.1±13  years  vs. 
44.75±12.4  years;  p=0.1).  In  addition,  t-test  analysis 
revealed that the risk of malignancy increased with 
age compared to those with no cancer (46.2±12.9 years 
vs 37.7±15.2 years, p<0.001). Mean age at tumor di-
agnosis was 50.8±13.2 years (range 15.5-82 years), and 
the average time between transplantation and detec-
tion of malignancy was 50.0±48.4 months (median 36, 
range 1-284 months). The lowest and highest median 
times to development of cancer were observed in KS 
and  GU  &  RS  malignancy  (13  months,  range  2-143 
months  vs  72  months,  8-240  months),  respectively 
(table 2). 
 
 
Table 2: Median time for diagnosis and follow up after 
transplantation. 
Median time (month)  KS  Non-KS PTLD  GU & 
RS 
Solid 
tumor 
Transplantation until 
diagnosis (month) 
13  60  46  72  36 
follow up period 
(month) 
23  34  12  12  9 
Non-KS: Non Kaposi’s sarcoma, KS: Kaposi’s sarcoma, PTLD: post 
transplantation lymphoproliferative disorder, GU & RS: genitouri-
nary and reproductive system. 
 
 
Tumor incidence  
Overall,  tumor  incidence  of  cancer  in  renal 
transplants was 2% and cumulative incidences of any 
detected  malignancy  after  kidney  transplantation 
during first 3 years are summarized in table 3. PTLD 
was the most common type of malignancy in age be-
low 30 years as well as age between 30-50 years (18 
cases; 54.5% and 36 cases; 30%, respectively). How-
ever, KS was the most common type of tumor (26 pa-
tients; 24.8%) in above 50 years old patients. The ma-
jority  of  patients  with  KS  had  limited  skin  and/or 
mucosal  disease  (87%  of  recipients),  while  13%  of 
them had visceral involvement. The skin cancer (141 
recipients; 52.9%) was the most frequently observed 
malignancy after renal transplantation including KS, 
SCC, BCC and melanoma, followed by PTLD (72 cas-
es; 27%); whereas GU & RS tumors (25 cases; 9.4%) 
was the most common malignancy among the other 
visceral tumors. The most frequent tumor in men and 
women  was  KS  (53  patients;  61.9%  and  31  cases; 
38.1%, respectively), which had low  mortality (n=7; 
11.1% and n=5; 15.6%, respectively) (table 4). 
RCC was seen in 6 patients of which 2 (33.3%) 
suffered from native RCC. We also observed a case of 
breast cancer in a male patient.  
AZA-based regimens was used in approximately 
one third of recipients (4771 cases; 38.1%), while the 
rest  was  on  MMF-based  therapy  (7736  patients; 
61.9%). In addition, about one third of female gender 
(1703  cases;  35.7%)  was  treated  with  AZA.  In  this 
study,  the  incidence  of  cancer  in  men  was  signifi-
cantly  greater  than  in  women  (67.8%  vs  32.2%, 
p=0.009)  and  recipients  who  were  on  AZA-based 
regimens  were  significantly  associated  with  higher 
rate of cancer in comparison with those who were on 
MMF-based  immunosuppression  (61.3%  vs  38.7%, 
p<0.001).  The  most  common  malignancy  with 
AZA-based  protocol  was  PTLD,  while  KS  was  the 
most frequently observed tumor in MMF-based reg-
imens (table 1). On the other hand, AZA-based im-
munosuppression was associated with a higher risk 
for development of PTLD when compared to MMF 
therapy (45.3% vs 54.7%, p=0.001).  
Tumors  developed  in  36  (13.5%)  of  patients 
treated with ALG/ATG (table 1). In this  study, the 
risk of malignancy was greatest in patients with age 
older than 30 (222 cases, 87.1%) (p= 0.007). However, 
no  significant  association  was  observed  between 
cancer  and  patients’  gender  [177  male  (2.2%)  vs  84 
female (1.8%), p=0.1].  
Treatment modalities 
Patients were treated with 2 strategies, first of all, 
standard  therapy  for  malignancy  and  the  second, 
immunosuppressive  modality.  Combined  surgery, 
chemotherapy  and  radiotherapy  in  22.95  percent; 
combined surgery and chemotherapy in 10.7 percent; 
combined  surgery  and  radiotherapy  in  3.8  percent; 
combined chemotherapy and radiotherapy among 4.6 
percent of patients were performed. In addition, sin-
gle  standard  treatment  with  surgery,  chemotherapy 
or  radiotherapy  was  done  among  26.7  percent,  29 
percent, and 2.3 percent respectively.  
Though withdrawal of calcineurin inhibitor and 
conversion to sirolimus should be considered early 
after the development of cancer; however, it had no 
significant  benefits  when  compared  to  reduction  of 
immunosuppressive therapy (p=1). However, reduc-
tion  of  immunosuppressive  agents  in  patients  with 
tumor  was  associated  with  lower  rate  of  graft  loss 
when  compared  to  the  withdrawal  of  immunosup-
pression (96.7% vs 73.9%, p<0.001). In addition, renal 
function  was  preserved  when  immunosuppression 
was reduced instead of withdrawn in recipients with 
cancer (96.7% vs 73.9%, p<0.001).   Journal of Cancer 2012, 3 
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Table 3: Frequency and cumulative incidence of malignancy. 
Cancer    Overall Incidence %  Frequency and cumulative incidence  Total frequency 
Freq1   Inc1%  Freq2  Inc2%  Freq3  Inc3%  frequency  percent  total 
GI  Colon  0.04      2  0.75      6  2.4  17 
Gastric  0.03      1  0.4      4  1.6 
Rectum  0.01  1  0.4          2  0.8 
pancreases  0.007          1  0.4  1  0.4 
hepatoma  0.02          2  0.75  3  1.2 
esophagus  0.007  1  0.4          1  0.4 
skin  SCC  0.3  5  1.9  4  3.3  1  3.7  40  13.5  141 
BCC  0.1  3  1.1  2  1.9  2  2.6  15  6.1 
Melanoma  0.01          1  0.4  2  0.8 
KS   0.6  40  14.3  15  16.9  8  20  84  31 
SCC+BCC  0.007              1  0.4 
GU & RS  Brest  0.02      1  0.4      3  1.2  25 
Uterin  0.01          1  0.4  2  0.8 
Ovary  0.02              3  1.2 
Prostat  0.007      1  0.4      1  0.4 
Seminoma  0.01      1  0.4      2  0.8 
RCC  0.04  1  0.4  1  0.75      6  2.4 
TCC  0.06  1  0.4          8  3.3 
Pulmonary  Mesothelioma  0.007  1  0.4          1  0.4  3 
lung  0.02  1  0.4      1  0.75  3  1.2 
PTLD    0.5  17  6.4  7  3.8  7  11.6  72  27.3  72 
Thyroid    0.01      1  0.4      2  0.8  2 
Parathyroid    0.007              1  0.4  1 
Chondrosarcoma    0.007              1  0.4  1 
Pelvic sarcoma    0.007      1  0.4      1  0.4  1 
Brain    0.02      1  0.4      3  1.2  3 
Freq1: frequency 1st year, Freq2: frequency 2nd year, Freq3: frequency 3rd year 
Inc1: incidence 1st year, Inc 2: incidence 2nd year, Inc 3: incidence 3rd year  
GI: gastrointestinal, GU & RS: genitourinary and reproductive system, PTLD: post transplantation lymphoproliferative disorder, KS: Ka-
posi’s sarcoma, SCC: squamouse cell carcinoma, BCC: basal cell carcinoma, RCC: renal cell carcinoma, TCC: transitional cell carcinoma 
 
Table 4: Cancer incidence based on age and sex distribution. 
Cancer    Male  Female  Age  Overall   
Median Tx-dig (mo)  N  %  N  %  ≤30 year  31-50 year  >50 year  frequency  percent  Total 
GI  Colon  27  6  3.4      1 (3)  2 (1.7)  3 (2.9)  6  2.4  17 
Gastric  43  2  1.1  2  2.4    2 (1.7)  2 (1.9)  4  1.6 
Rectum  57  2  1.1          2 (1.9)  2  0.8 
pancreace  32  1  0.6        1 (0.9)    1  0.4 
hepatoma  36  3  1.9        3 (2.6)    3  1.2 
esoghagus  8  1  0.6          1 (1)  1  0.4 
Skin  SCC  13  34  19.2  5  6  2 (6.1)  11 (9.4)  26 (24.8)  39  13.5  141 
BCC  39  11  6.2  3  3.6  1 (3)  4 (3.4)  9 (8.6)  15  6.1 
Melanoma  38  2  1.1        1 (0.9)  1 (1)  2  0.8 
KS  72  52  29.4  30  35.7  8 (24.2)  35 (29.9)  36 (34.3)  84  31 
SCC+BCC  76  1  0.6        1 (0.9)    1  0.4 
GU & RS  Brest  100  1  1.1  2  2.4    3 (2.6)    3  1.2  25 
Uterin  57      2  2.4      2 (1.9)  2  0.8  Journal of Cancer 2012, 3 
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Cancer    Male  Female  Age  Overall   
Median Tx-dig (mo)  N  %  N  %  ≤30 year  31-50 year  >50 year  frequency  percent  Total 
Ovary  72      3  3.6  1(3)  2 (1.7)    3  1.2 
Prostat  22  1  0.6          1 (1)  1  0.4 
Seminoma  22  2  1.1        1 (0.9)    2  0.8 
RCC  16  5  2.8  1  1.2    3 (2.6)  2 (1.9)  6  2.4 
TCC  81  5  2.8  3  3.6  1(3)  4 (3.4)  3 (2.9)  8  3.3 
Pulmonary  Mesothelioma  30  1  0.6        3 (2.6)    1  0.4  3 
Lung   8  2  1.1  1  1.2    1 (0.9)    3  1.2 
PTLD    46  42  23.7  28  33.3  18(54.5)  36 (30)  15 (14.3)  72  27.3  72 
Thyroid    24  2  1.1        2 (1.7)    2  0.8  2 
Parathyroid    120      1  1.2    1 (0.9)    1  0.4  1 
Chondrosar-
coma 
  132  1  0.6        1 (0.9)    1  0.4  1 
Pelvic sarcoma    14      1  1.2      1 (1)  1  0.4  1 
Brain     62  1  0.6  2  2.4  1 (3)  1 (0.9)  1 (1)  3  1.2  3 
Tx-dig: transplantation until diagnosis, N: number, mo: month, GI: gastrointestinal, GU & RS: genitourinary and reproductive system, 
PTLD: post transplantation lymphoproliferative disorder, KS: Kaposi’s sarcoma, SCC: squamouse cell carcinoma, BCC: basal cell carcinoma, 
RCC: renal cell carcinoma, TCC: transitional cell carcinoma 
 
Graft function 
Overall  death-censored  graft  loss  (graft  failure 
without death) was seen in 11.4% individuals; on the 
other  hand,  50  cases  died  with  a  functioning  graft. 
Thus, the main cause of graft loss in our recipients 
was patient death.  
Mortality rate 
At the end of the study, 25% (67) of RTRs died 
following  development  of  cancer.  A  higher  rate  of 
mortality was seen within the first year after tumor 
diagnosis (54 cases, 20.5%), while only 4.5% of mor-
tality  was  observed  during  the  next  5  years.  PTLD 
was the most common cause of death in both genders 
(20 male and 8 female) and in all age groups (3 in 
group  ≤30  years,  17  in  group  31-50  years  and  7  in 
group >50 years). 
Patient Survival Data    
In the current study, overall cumulative patient 
survival was 74.6% at 14 years after tumor diagnosis 
and  table  5  summarizes  the  first  5  year  cancer free 
survival  rates  in  5  groups.  In  addition,  cumulative 
survival curves are plotted separately for all groups in 
figure  1.  The  overall  mean  survival  time  was  117.1 
months (95% CI: 104.9-129.2) and for all categorized 
cancer  groups,  data  are  shown  in  table  6.  The  best 
overall mean survival rates after treatment of malig-
nancy  were  observed  in  patients  with  SCC  or  BCC 
(non-KS  group)  which  was  164.8  months  (95%  CI: 
158.7-170.9), and the worst prognosis was associated 
with  sub-group  of  solid  tumor  (mean  25.5  months; 
95% CI: 12.7-38.2). 
In univariate analysis, the significant risk factors 
for  death  included  poor  graft  function  (p<0.001), 
treatment with AZA (P=0.004), acute rejection episode 
after  transplantation  (P=0.008),  withdrawal  of  im-
munosuppressive  drugs  (p<0.001),  non  skin  tumors 
(p<0.001), distant metastasis (P<0.001), no response to 
treatment  (p<0.001),  and  induction  therapy  with 
ATG/ALG (p=0.02).  
In  multivariate  analysis,  the  only  independent 
risk factor associated with mortality was type of ma-
lignancy (table 7).  
 
Table 5: Survival rate. 
cancer  1st year  2nd year  3rdyear  4 th year  5 th year 
KS  77 (91.7)  74 (88.1)  73 (86.9)  73 (86.9)  72 (85.7) 
PTLD  44 (62)  43 (63.6)  43 (60.6)  43 (60.6)  43 (60.6) 
Solid  13 (46.4)  12 (42.9)  12 (42.9)  12 (42.9)  12 (42.9) 
GU & RS  19 (79.2)  17 (70.8)  16 (66.7)  16 (66.7)  15 (62.5) 
Non-KS  57 (100)  56 (98.2)  56 (98.2)  56 (98.2)  56 (98.2) 
PTLD: post transplantation lymphoproliferative disorder, KS: Ka-
posi’s sarcoma, Non-KS: Non-KS: Kaposi’s sarcoma, GU & RS: 
genitourinary and reproductive system. 
Table 6: Mean survival time. 
cancer  Mean  95% CI 
KS  132.26   13.4-151.7 
PTLD  96.03  78.6-113.4 
Solid tumors  25.49  12.7-38.2 
GU & RS   36.23  23.4-49.06 
Non-KS  164.8  158.7-170.9 
PTLD: post transplantation lymphoproliferative disorder, KS: Ka-
posi’s sarcoma, Non-KS: Non-KS: Kaposi’s sarcoma, GU & RS: 
genitourinary and reproductive system.  Journal of Cancer 2012, 3 
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Table 7: Relative risk of cancers after transplantation compared with skin tumors. 
  First year  Second year  Third & fourth year  Fifth year  overall 
  RR (95% CI) P  RR (95% CI) P  RR (95% CI) P  RR (95% CI) P  RR (95% CI) P 
Skin  1  1  1  1  1 
PTLD  33.6 (7.4-152.4) 0  37.1 (8.1-170.4) 0  28.1 (7.6-106.6) 0  28.5 (7.6-106.6) 0  28.5 (7.5-106.6) 0 
Solid  27.5 (5.6-113.6) 0  35.4 (7.3-170.5) 0  28.4 (7.04-114.5) 0  28.4 (7.04-114.5) 0  28.4 (7.05-114.5) 0 
GU & RS  34.6 (4.8-246.8) 0  39.9 (5.4-291.6) 0  31.9 (5.03-203.3) 0  31.9 (5.03-203.2) 0  31.9 (5.03-203.3) 0 
PTLD: post transplantation lymphoproliferative disorder, GU & RS: genitourinary and reproductive system. 
 
 
 
 
 
Fig 1: cumulative survival of categorized malignancy after kidney transplantation. KS: Kaposi’s sarcoma; PTLD: post transplantation 
lymphoproliferative disorder; Non KS: Non Kaposi’s sarcoma tumors; GU & RS: genitourinary & reproductive system. 
 
 
DISSCUSION 
With  the  advent  of  management  for  infectious 
and  cardiovascular  complications  after  renal  trans-
plantation,  it  is  probable  that  malignancy  among 
RTRs may become an increasingly essential cause of 
mortality  in  the  future  (18).  To  the  best  of  our 
knowledge, this is the largest series reporting the re-
sults of post-transplant malignancy in LURT patients. 
According  to  some  reports,  incidence  of 
post-transplant  cancer  ranges  from  2%  to  31%  (de-
pending  on  the  follow-up  period,  tumor  kind  and 
registry records) and adds up to 34–50% (6). However, 
in this study the overall tumor incidence in RTRs was 
2% which is less than other studies, even from Asian 
reports (1, 4, 6, 7, 14, 21-24). On the other hand, the 
relative risk for cancer in post-transplant recipients is 
different among the various cancers. The reasons for 
these differences are given below: 
1- The available studies are limited, because the 
main information on cancer in the renal transplanted 
patients  is  adopted  from  the  Cincinnati  Transplant 
Tumor Registry, Collaborative Transplant Study, and 
the Australian and New Zealand Transplant Registry 
(3),  which  are  in  a  limited  location  with  a  relative 
homogeneity  in  medical  care,  type  of  donor,  geo-
graphical  location,  disease  epidemiology,  lifestyle, 
diet, cultural and socioeconomic status. For example  Journal of Cancer 2012, 3 
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regional differences can explain reason of higher skin 
cancers  rate  in  Australia  and  New  Zealand  versus 
Central Europe (3).  
 Also,  reporting  of  cancer  to  registries  is  often 
incomplete  and  probably  underestimates  the  true 
cancer incidence which potentially leads to difference 
in overall cancer incidence. On the other hand, single 
center studies have small sample size therefore are not 
reliable then using data from different registries, with 
different population can help to estimate almost true 
incidence of cancers (25).  
2- Several specific malignancies in transplant re-
cipients have been linked with specific viruses, such 
as  Epstein–Barr  virus  (EBV)  which  promotes  lym-
phomas as well as hepatitis viruses B and C which are 
linked  with  hepatocellular  carcinoma  and  human 
herpes virus 8 which predisposes to lymphomas and 
Kaposi’s  sarcoma.  In  addition,  cervical,  penile  and 
vulvar cancers are associated with human papilloma-
viruses (25). As we know, distribution of viruses is 
epidemiologically  different  and  so  the  difference  in 
distribution of viruses induced cancers are expected. 
3-  Published  studies  show  that  geographical 
factors  have  also  an  impact  on  different  forms  of 
post-transplant  cancer,  since  high  incidence  of  gas-
trointestinal tumors in Japan, urinary tract transitional 
cell  carcinoma  in  Taiwan  and  liver  cancer  in 
South-East Asia have been reported in kidney trans-
plant recipients (25, 26). 
4- Exposure to carcinogens such as total sun ex-
posure  and  living  in  a  hot  climate  which  are  im-
portant risk factors for skin cancers, and difference in 
race as well as genetics can cause difference in skin 
cancer distribution. For example, studies have shown 
that Caucasian RTRs living in Queensland, Australia, 
have  the  highest  global  risk  of  non-melanoma  skin 
cancer (NMSC) (25, 27). 
5- Samhan et al revealed that cancer after kidney 
transplantation  was  more  frequent  in  deceased  do-
nors (15). 
6- Wimmer et al showed time and the intensity 
of  immunosuppression  augmented  the  incidence  of 
malignancy  (3),  therefore  the  races  such  as  African 
who need more immunosuppressive drugs after kid-
ney transplantation are more predisposed to cancer 
(28). 
Although in this study following up period was 
not very long, lower incidence of malignancy may be 
due to living donors, strict screening, exact immuno-
suppressive monitoring, lower doses of immunosup-
pression used in RTRs from living donors, race and 
lifestyle differences which need further investigation.  
Skin cancer 
In contrast to Moosa and Gralla study which be-
lieves Middle East RTRs rarely have skin malignan-
cies (29): in this study, the skin cancer was the most 
common form of malignancy among RTRs, a finding 
that  is  concordant  with  other  reports  (18),  but  the 
most common type of skin cancer in  our recipients 
was different from Western countries and similar to 
Mediterranean, Jewish, Arabic, Caribbean, or African 
reports  which  KS  is  the  most  frequently  observed 
tumor among our RTRs (3, 7, 10, 20). 
SCC and BCC have better prognosis than KS. On 
the other hand, race and geographic location are the 
important  factors  for  incidence  of  KS;  therefore,  it 
seems  that  race  and  geographic  location  may  be 
prognostic factors in post-transplant malignancy.  
In post-transplant skin cancer, immunosuppres-
sive agents such as azathioprine or cyclosporine not 
only can directly potentiate damaging effects of UV 
radiation on skin, but also can augment reduction of 
local  and  systemic  immune  responses  during  sun 
exposure. Furthermore, azathioprine sensitizes DNA 
to  UVA  radiation,  reducing  the  minimal  erythema 
dose in skin cells of treated patients (30, 31). In one 
study, a significant association between current use of 
azathioprine and cutaneous SCC was described (27, 
32) 
PTLD 
In  adults,  PTLD  is  the  second  most  common 
cancer and encompasses up to 12% of post-transplant 
cancers (18). In children with renal transplant, PTLD 
is the most common cancer which involves up to 50% 
of post-transplant cancers (18). It was 4-fold higher in 
children  than  adults  (33).  The  frequency  of  PTLD 
varies  according  to  the  type  of  organ  transplanted, 
age of recipients (i.e., children versus adults), and the 
immunosuppressive  regimen  (33).  Furthermore,  re-
cipients developing PTLD after organ transplantation 
have a poor prognosis (25). In the current study, in-
cidence of PTLD was 0.5% and majority of them are 
presented in the first year (6.4%), and survival rate is 
lower especially in the first years (Fig 1). 
GU & RS tumors 
According to Dantal study (2007) (25) about GU 
& RS cancer in RTRs the most common GU & RS tu-
mors  is  transitional  cell  carcinoma  and  majority  of 
them  were diagnosed at early stage and capable of 
treatment (25, 34). Moreover, Besarani et al. (2006) (34) 
reported  the  incidence  of  urological  tumors  in  the 
Oxford Transplant Centre among 2100 RTRs within 3 
decades  and  RCC  accounted  for  the  most  common 
urological malignancies in these individuals with an  Journal of Cancer 2012, 3 
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incidence of 4.6%. In our study, the majority of GU & 
RS cancers were late onset with low survival rate and 
they presented more in middle age and in male gen-
der. Therefore, screening schedules are very helpful 
for early detection and it is reasonable that all patients 
after  transplantation  must  be  monitored  for  TCC 
bladder and for both native and transplanted kidney 
with a regular ultrasonography.  
In this  study,  we found a lower prevalence  of 
breast  cancers  (male/female:  1/2)  in  our  recipients. 
However, there is no consensus whether female renal 
transplant patients rarely got breast cancer. Marcen et 
al  (35)  believe  prostate  cancer  in  male  and  breast 
cancer in female gender which are one of the most 
common neoplasias in general population, are not (or 
only slightly) increased among transplant recipients. 
Nevertheless, Kasiske et al (10) reported a 2-fold in-
crease in breast cancer risk among RTRs compared to the 
general population (10). Interestingly, breast cancer is 
known  to  be  a  hormonally  dependent  carcinoma. 
Many studies have revealed androgen receptor to be 
often  co-expressed  with  estrogen  receptor  and  pro-
gesterone receptor in breast tumors (36).  
The main contributing factors of malignancy in 
kidney transplant patients: 
Solid tumors 
We found that the worst prognosis was observed 
in solid tumors patients with high rate of refractori-
ness to treatment and elevated recurrence rate.  
Immunosuppression 
One of the most important risk factors for de-
veloping malignancies is receiving immunosuppres-
sive agents (25), they can affect host defense and sus-
ceptible  to  malignancy  (18).  Conversely,  some  im-
munosuppressive  drugs  for  instance  sirolimus  has 
dual  effect  on  immunosuppression  and  antitumor 
effect experimentally and clinically. Published studies 
have  revealed  a  lesser  incidence  of  new  (de  novo) 
malignancies in RTRs whose immunosuppression is 
mTOR  inhibitors  than  CNIs.  One  of  the  important 
advantage in mTOR inhibitors usage may be the pro-
tection  of  allograft  from  immunological  rejection, 
while  simultaneously  preventing  from  cancer  in 
high-risk group (21). 
Although,  while  considering  patient  survival 
until now, any meticulous immunosuppressive pro-
tocol has not been confirmed to be better over others, 
but it seems AZA and calcineurin inhibitors (CNIs) 
have  been  more  linked  with  post-transplant  malig-
nancies (2). In this study, MMF had less negative im-
pact on the incidence of malignancies than AZA. In 
the current study, all types of malignancies were as-
sociated  with  AZA  based  protocol  except  for  KS 
which was associated with MMF slightly more than 
AZA  based  regimen.  Data  about  carcinogenicity  of 
MMF  are  controversial  (25).  While  MMF  was  diag-
nosed as an anti-neoplastic agent, some clinical trials 
suggested that it was associated with a non-significant 
tendency towards an increased risk of PTLD in RTRs 
(37), but PTLD was significantly associated with AZA 
in our patients. On the other hand, two large studies 
demonstrated that MMF was not linked with ampli-
fication of malignancy (38, 39). Indeed, it seems that 
there is a trend towards a lower risk of malignancy 
with MMF (25, 38). 
According to other studies in malignant condi-
tion, we preferred to change calcineurin inhibitor by 
sirolimus. However, it was not available until recent 
years  and  reduction  or  withdrawal  of  immunosup-
pressive  drugs  was  mostly  achieved.  Nonetheless, 
decrease  of  immunosuppression  had  significantly 
better results in terms of response to treatment, pre-
vention  of  rejection,  graft  preservation  and  patient 
survival  compared  to  immunosuppressive  discon-
tinuation.  Finally,  induction  of  donor-specific  toler-
ance might be resolved so many complications from 
long-term  immunosuppressive  therapies  in  future 
(40).  
Survival  
Despite  the  high  incidence  of  skin  cancers  in 
transplant  recipients,  these  tumors  are  usually  not 
fatal. Solid organ cancers, although less common, are 
associated with a far worse prognosis in renal trans-
plant recipients (25). The best survival has been ob-
served  in  SCC  and  BCC  and  the  worst  in 
non-hematologic  and  non-skin  tumors.  Patient  sur-
vival  is  lesser  in  patients  who  received  monoclonal 
antibody induction. Thus if monoclonal antibody in-
duction  is  indicated,  consideration  to  benefit  and 
hazard, in future, is very important. 
Although the present results showed no signifi-
cant difference between gender, age, type of immu-
nosuppression and all type of cancers, we found that 
the majority of cancers occurred in the first 5 years 
after  transplantation,  male  gender,  patients  greater 
than 40 years, individuals received AZA. Thus, these 
groups should be considered for screening protocols.  
LIMITATION 
As  this  study  was  retrospective  and  data  has 
been  collected  from  previous  medical  records  that 
were completed by several nephrologists without any 
coordination  between  them,  thus  all  contributing 
factors were not accessible and we have some missing 
data. In addition follow up period was short and we  Journal of Cancer 2012, 3 
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did not follow patients who developed cancer after 
transplant failure. 
Unfortunately,  we  have  no  document  reports 
about all kind of malignancy in non-transplant pop-
ulation;  subsequently,  comparison  of  cancer  rate  in 
transplant patients with the general population was 
not possible. 
CONCLUSION 
This study revealed the lowest malignancy inci-
dence in living unrelated kidney transplantation and 
KS  as  the  most  common  malignancy  in  our  RTRs. 
Additionally, immunosuppressive reduction has bet-
ter outcome than withdrawal. Otherwise, use of im-
munosuppressive agents must be balanced between 
the beneficial or hazardous effect of preventing organ 
rejection or increasing the risk of tumor development.  
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